|
Aurobindo Pharma Limited has registered a total
income of Rs.4169.7 million (Rs.3233.4 million),
EBITDA of Rs. 661.5 million (Rs.361.4 million)
and PAT of Rs.261.9 million (Rs.105.9 million)
for the quarter ended December 31, 2005 |
|
During the quarter
the sales, EBITDA and PAT had shown a growth of
28%, 83% and 147% respectively as compared to
the corresponding quarter of previous year.
EBITDA stands at 16%(11%) of sales. |
|
The company's
investments in the regulated markets have begun
to show results. Export sales during the quarter
stood at Rs. 2338 million (Rs.1523 million)
registering a growth of 54%. Exports now
constitute 57% ($*%) of total sales. |
|
The formulations
sales have grown by 125% to Rs.925 million
(Rs.412 million) and now constitute 23% (13%) of
total sales. |
|
The increased number
of the regulatory approvals is expected to keep
up the buoyancy in the formulations exports. |
|
Ramping up of
filings in US |
|
Particulars |
Q3 FY06 |
Cumulative as on
Dec 31, 2005 |
| |
USA |
USA |
|
DMFs |
13 |
54 |
|
ANDAs |
10 |
45 |
|
|
During the quarter
Aurobindo has filed 10 ANDAs and 13 DMFs for US
and has filed 70 formulations filings in other
markets. The total number of formulations
filings now stands at 364. |
|
Aurobindo has filed
additional 11 patents during the quarter and the
cumulative filings stand at 163 as of December
31, 2005. |
|
US Market |
|
Aurobindo is gaining
acceptance in the USD market and the business in
contributing to the performance of the company.
Aurobindo has received final approval for
Amoxicillin Tablets and Capsules, Cephalexin
Capsules and Mirtazapine Orally Disintegrating
Tablets (ODT) during this quarter enabling
Aurobindo expand the product portfolio for the
US market. |
|
PEPFAR Program |
|
During the quarter,
Aurobindo had received 3 approvals. US FDA
tentatively approved Lamivudine Oral Solution,
Stavudine Oral Solution and Nevirapine Oral
Suspension further strengthening the product
portfolio. Aurobindo's portfolio of products for
the PEPFAR program now stands at10. |
|
Europe Market |
|
European market is
one of the Key markets and Aurobindo has
established subsidiaries / branch offices in
Netherlands, Italy and UK. During the quarter
Medicine and Health products Regulatory Agency
(UK MHRA) approved its first formulation product
for Sertraline Hydrochloride Tablets. During the
quarter Aurobindo has received the approval for
API Flucloxacillin Sodium By European
Directorate for the Quality of Medicines (EDQM). |
|
Facility approval by
UK MHRA |
|
UK MHRA has
recommended Aurobindo's Unit XII as a site to
manufacture formulations for the UK market.
Apart from this approval, the Unit XII facility
is also approved by other accredited regulatory
agencies. |
|
Surge in WHO
Pre-qualification list |
|
During the
quarter 8 ARV products of Aurobindo have been
included in the WHO pre-qualification list.
Aurobindo's Nevirapine oral suspension,
Stavudine oral solution and Efavirenz tablets
are the first generics included by WHO in its
program. As on date 10 products are included in
the WHO pre-qualification list. |
|
Patent appreciation award |
|
Aurobindo won
the Patent Appreciation Award facilitated by The
Indian Drug Manufacturers Association (IDMA) for
three of its patents |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The Company is
marketing these products globally, in over 100
countries. |
PRESS
ROOM
